The trends driving ELRIG Drug Discovery 2022
Drug Discovery World
OCTOBER 4, 2022
The trial will see Bayer using its subsidiary BrainVectis to investigate its gene therapy, BV-101 in the treatment for Huntington’s Disease (HD). The company is currently proceeding with a Phase II clinical trial in Canada for the clinical validation of psilocybin for the treatment of alcohol use disorder (AUD). .
130 
Let's personalize your content